{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:50:47Z","timestamp":1790052647886,"version":"4.0.1"},"reference-count":40,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAR"],"published-print":{"date-parts":[[2018,12,31]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Positron-emission-tomography (PET) using 18F labeled florbetaben allows noninvasive in vivo-assessment of amyloid-beta (A\u03b2), a pathological hallmark of Alzheimer\u2019s disease (AD). In preclinical research, [&lt;sup&gt;18&lt;\/sup&gt;F]-florbetaben-PET has already been used to test the amyloid-lowering potential of new drugs, both in humans and in transgenic models of cerebral amyloidosis. The aim of this study was to characterize the spatial pattern of cerebral uptake of [&lt;sup&gt;18&lt;\/sup&gt;F]-florbetaben in the APPswe\/ PS1dE9 mouse model of AD in comparison to histologically determined number and size of cerebral A\u03b2 plaques.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Both, APPswe\/PS1dE9 and wild type mice at an age of 12 months were investigated by smallanimal PET\/CT after intravenous injection of [&lt;sup&gt;18&lt;\/sup&gt;F]-florbetaben. High-resolution magnetic resonance imaging data were used for quantification of the PET data by volume of interest analysis. The standardized uptake values (SUVs) of [&lt;sup&gt;18&lt;\/sup&gt;F]-florbetaben in vivo as well as post mortem cerebral A\u03b2 plaque load in cortex, hippocampus and cerebellum were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Visual inspection and SUVs revealed an increased cerebral uptake of [&lt;sup&gt;18&lt;\/sup&gt;F]-florbetaben in APPswe\/ PS1dE9 mice compared with wild type mice especially in the cortex, the hippocampus and the cerebellum. However, SUV ratios (SUVRs) relative to cerebellum revealed only significant differences in the hippocampus between the APPswe\/PS1dE9 and wild type mice but not in cortex; this differential effect may reflect the lower plaque area in the cortex than in the hippocampus as found in the histological analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>The findings suggest that histopathological characteristics of A\u03b2 plaque size and spatial distribution can be depicted in vivo using [&lt;sup&gt;18&lt;\/sup&gt;F]-florbetaben in the APPswe\/PS1dE9 mouse model.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1567205015666181022095904","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T12:02:11Z","timestamp":1540209731000},"page":"49-55","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["[<sup>18<\/sup>F]-florbetaben PET\/CT Imaging in the Alzheimer\u2019s Disease Mouse Model APPswe\/PS1dE9"],"prefix":"10.2174","volume":"16","author":[{"given":"J.","family":"Stenzel","sequence":"first","affiliation":[{"name":"Core Facility Multimodal Small Animal Imaging, Rostock University Medical Center, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"R\u00fchlmann","sequence":"additional","affiliation":[{"name":"Institute for Experimental Surgery, Rostock University Medical Center, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lindner","sequence":"additional","affiliation":[{"name":"Core Facility Multimodal Small Animal Imaging, Rostock University Medical Center, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Polei","sequence":"additional","affiliation":[{"name":"Core Facility Multimodal Small Animal Imaging, Rostock University Medical Center, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Teipel","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases (DZNE) - Rostock\/Greifswald, Rostock, Germany, Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kurth","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Rostock University Medical Center, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rominger","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.J.","family":"Krause","sequence":"additional","affiliation":[{"name":"Core Facility Multimodal Small Animal Imaging, Rostock University Medical Center, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Vollmar","sequence":"additional","affiliation":[{"name":"Core Facility Multimodal Small Animal Imaging, Rostock University Medical Center, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kuhla","sequence":"additional","affiliation":[{"name":"Institute for Experimental Surgery, Rostock University Medical Center, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0301-0082(99)00033-7","volume":"60","author":"Czech C.","year":"","unstructured":"Czech C, Tremp G, Pradier L. Prog Neurobiol, Presenilins and Alzheimer\u2019s disease: biological functions and pathogenic mechanisms.,, , 60,, 363-384,(2000).","journal-title":"Prog Neurobiol"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0197-4580(97)00066-3","volume":"18","author":"Hyman B.T.","year":"","unstructured":"Hyman BT. Neurobiol Aging, The neuropathological diagnosis of Alzheimer\u2019s disease: clinical-pathological studies.,, , 18,, S27-S32,(1997).","journal-title":"Neurobiol Aging"},{"key":"ref=3","first-page":"F98","volume":"164","author":"Villars H.","year":"","unstructured":"Villars H, Gillioz AS, Hein C, Voisin T, Nourhashemi F, Soto ME. Rev Neurol (Paris), Alzheimer\u2019s disease and syndromes related to the severe stage.,, , 164,, F98-F106,(2008).","journal-title":"Rev Neurol (Paris)"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jalz.2008.05.2479","volume":"4","author":"Ziegler-Graham K.","year":"","unstructured":"Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM. Alzheimers Dement, Worldwide variation in the doubling time of Alzheimer\u2019s disease incidence rates.,, , 4,, 316-323,(2008).","journal-title":"Alzheimers Dement"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1590\/S1807-59322011001300003","volume":"66","author":"Ferreira L.K.","year":"","unstructured":"Ferreira LK, Busatto GF. Clinics (S\u00e3o Paulo), Neuroimaging in Alzheimer\u2019s disease: current role in clinical practice and potential future applications.,, , 66,, 19-24,(2011).","journal-title":"Clinics (S\u00e3o Paulo)"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"Bateman R.J.","year":"","unstructured":"Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC. N Engl J Med, Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease.,, , 367,, 795-804,(2012).","journal-title":"N Engl J Med"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"Rinne J.O.","year":"","unstructured":"Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE. Lancet Neurol, 11C-PiB PET assessment of change in fibrillar amyloid-\u03b2 load in patients with Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.,, , 9,, 363-372,(2010).","journal-title":"Lancet Neurol"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S0197-4580(97)00062-6","volume":"18","author":"Braak H.","year":"","unstructured":"Braak H, Braak E. Neurobiol Aging, Diagnostic criteria for neuropathologic assessment of Alzheimer\u2019s disease.,, , 18,, S85-S88,(1997).","journal-title":"Neurobiol Aging"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/WNL.41.4.479","volume":"41","author":"Mirra S.S.","year":"","unstructured":"Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM. Neurology, The consortium to establish a registry for Alzheimer\u2019s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease.,, , 41,, 479-486,(1991).","journal-title":"Neurology"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/00005072-199911000-00004","volume":"58","author":"Newell K.L.","year":"","unstructured":"Newell KL, Hyman BT, Growdon JH, Hedley-Whyte ET. J Neuropathol Exp Neurol, Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease.,, , 58,, 1147-1155,(1999).","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"Dubois B.","year":"","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K. Lancet Neurol, Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria.,, , 13,, 614-629,(2014).","journal-title":"Lancet Neurol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","volume":"7","author":"Jack C.R.","year":"","unstructured":"Jack CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC. Alzheimers Dement, Introduction to the recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.,, , 7,, 257-262,(2011).","journal-title":"Alzheimers Dement"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.bbadis.2011.11.005","volume":"1822","author":"Vlassenko A.G.","year":"","unstructured":"Vlassenko AG, Benzinger TL, Morris JC. Biochim Biophys Acta, PET amyloid-beta imaging in preclinical Alzheimer\u2019s disease.,, , 1822,, 370-379,(2012).","journal-title":"Biochim Biophys Acta"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2967\/jnumed.112.104810","volume":"53","author":"Brockschnieder D.","year":"","unstructured":"Brockschnieder D, Schmitt-Willich H, Heinrich T, Varrone A, Guly\u00e1s B, Toth M. J Nucl Med, Preclinical characterization of a novel class of 18F-labeled PET tracers for amyloid-\u03b2.,, , 53,, 1794-1801,(2012).","journal-title":"J Nucl Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/gps.2640 (2011).","volume":"26","author":"Quigley H.","year":"","unstructured":"Quigley H, Colloby SJ, O\u2019Brien JT. Int J Geriatr Psychiatry, PET imaging of brain amyloid in dementia: a review.,, , 26,, 991-999,10.1002\/gps.2640 (2011).","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"Klunk W.E.","year":"","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP. Ann Neurol, Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B.,, , 55,, 306-319,(2004).","journal-title":"Ann Neurol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(04)00853-1","volume":"3","author":"Nordberg A.","year":"","unstructured":"Nordberg A. Lancet Neurol, PET imaging of amyloid in Alzheimer\u2019s disease.,, , 3,, 519-527,(2004).","journal-title":"Lancet Neurol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","volume":"68","author":"Rowe C.C.","year":"","unstructured":"Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G. Neurology, Imaging beta-amyloid burden in aging and dementia.,, , 68,, 1718-1725,(2007).","journal-title":"Neurology"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","volume":"67","author":"Mintun M.A.","year":"","unstructured":"Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH. Neurology, [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.,, , 67,, 446-452,(2006).","journal-title":"Neurology"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.22248","volume":"69","author":"Villemagne V.L.","year":"","unstructured":"Villemagne VL, Pike KE, Ch\u00e9telat G, Ellis KA, Mulligan RS, Bourgeat P. Ann Neurol, Longitudinal assessment of A\u03b2 and cognition in aging and Alzheimer disease.,, , 69,, 181-192,(2011).","journal-title":"Ann Neurol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"Rowe C.C.","year":"","unstructured":"Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O\u2019Keefe G. Lancet Neurol, Imaging of amyloid \u03b2 in Alzheimer\u2019s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.,, , 7,, 129-135,(2008).","journal-title":"Lancet Neurol"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.109.069088","volume":"51","author":"Wong D.F.","year":"","unstructured":"Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT. J Nucl Med, In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand [18F]-AV-45 (florbetapir [corrected] F 18).,, , 51,, 913-920,(2010).","journal-title":"J Nucl Med"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.22068","volume":"68","author":"Vandenberghe R.","year":"","unstructured":"Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E. Ann Neurol, 18F-Flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.,, , 68,, 319-329,(2010).","journal-title":"Ann Neurol"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","volume":"52","author":"Villemagne V.L.","year":"","unstructured":"Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G. J Nucl Med, Amyloid imaging with 18F-Florbetaben in Alzheimer disease and other dementias.,, , 52,, 1210-1217,(2011).","journal-title":"J Nucl Med"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"Barthel H.","year":"","unstructured":"Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K. Lancet Neurol, Cerebral amyloid-\u03b2 PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: a multicentre phase 2 diagnostic study.,, , 10,, 424-435,(2011).","journal-title":"Lancet Neurol"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13550-015-0090-6","volume":"5","author":"Yousefi B.H.","year":"","unstructured":"Yousefi BH, von Reutern B, Scher\u00fcbl D, Manook A, Schwaiger M, Grimmer T. EJNMMI Res, FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice.,, , 5,, 20-,(2015).","journal-title":"EJNMMI Res"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/brain\/awt142","volume":"136","author":"Ni R.","year":"","unstructured":"Ni R, Gillberg PG, Bergfors A, Marutle A, Nordberg A. Brain, Amyloid tracers detect multiple binding sites in Alzheimer\u2019s disease brain tissue.,, , 136,, 2217-2227,(2013).","journal-title":"Brain"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.nucmedbio.2012.03.001","volume":"39","author":"Fodero-Tavoletti M.T.","year":"","unstructured":"Fodero-Tavoletti MT, Brockschnieder D, Villemagne VL, Martin L, Connor AR, Thiele A. Nucl Med Biol, In vitro characterization of [18F]-florbetaben, an A\u03b2 imaging radiotracer.,, , 39,, 1042-1048,(2012).","journal-title":"Nucl Med Biol"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2967\/jnumed.112.114660","volume":"54","author":"Rominger A.","year":"","unstructured":"Rominger A, Brendel M, Burgold S, Keppler K, Baumann K, Xiong G. J Nucl Med, Longitudinal assessment of cerebral A\u03b2 deposition in mice overexpressing Swedish mutant A\u03b2 precursor protein using 18F-florbetaben PET.,, , 54,, 1127-1134,(2013).","journal-title":"J Nucl Med"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"e0116678","DOI":"10.1371\/journal.pone.0116678","volume":"10","author":"Brendel M.","year":"","unstructured":"Brendel M, Jaworska A, Grie\u00dfinger E, R\u00f6tzer C, Burgold S, Gildehaus FJ. PLoS One, Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models.,, , 10,, e0116678-,(2015).","journal-title":"PLoS One"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/mp.2015.74","volume":"20","author":"Brendel M.","year":"","unstructured":"Brendel M, Jaworska A, Herms J, Trambauer J, R\u00f6tzer C, Gildehaus FJ. Mol Psychiatry, Amyloid-PET predicts inhibition of de novo plaque formation upon chronic \u03b3-secretase modulator treatment.,, , 20,, 1179-1187,(2015).","journal-title":"Mol Psychiatry"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"517160","DOI":"10.4061\/2011\/517160","volume":"2011","author":"Malm T.","year":"","unstructured":"Malm T, Koistinaho J, Kanninen K. Int J Alzheimers Dis, Utilization of APPswe\/PS1dE9 Transgenic Mice in Research of Alzheimer\u2019s Disease: focus on Gene Therapy and Cell-Based Therapy Applications.,, , 2011,, 517160-,(2011).","journal-title":"Int J Alzheimers Dis"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"22707","DOI":"10.1074\/jbc.M611050200","volume":"282","author":"Jankowsky J.L.","year":"","unstructured":"Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, Lester HA. J Biol Chem, Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice.,, , 282,, 22707-22720,(2007).","journal-title":"J Biol Chem"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12264-011-1015-7","volume":"27","author":"Xiong H.","year":"","unstructured":"Xiong H, Callaghan D, Wodzinska J, Xu J, Premyslova M, Liu QY. Neurosci Bull, Biochemical and behavioral characterization of the double transgenic mouse model (APPswe\/PS1dE9) of Alzheimer\u2019s disease.,, , 27,, 221-232,(2011).","journal-title":"Neurosci Bull"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.nicl.2017.06.009","volume":"15","author":"Kuhla A.","year":"","unstructured":"Kuhla A, R\u00fchlmann C, Lindner T, Polei S, Hadlich S, Krause BJ. Neuroimage Clin, APPswe\/PS1dE9 mice with cortical amyloid pathology show a reduced NAA\/Cr ratio without apparent brain atrophy: A MRS and MRI study.,, , 15,, 581-586,(2017).","journal-title":"Neuroimage Clin"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.neurobiolaging.2011.12.024","volume":"33","author":"Poisnel G.","year":"","unstructured":"Poisnel G, Dhilly M, Mousti\u00e9 O, Delamare J, Abbas A, Guilloteau D, Barr\u00e9 L. Neurobiol Aging, PET imaging with [18F]AV-45 in an APP\/PS1-21 murine model of amyloid plaque deposition.,, , 33,, 2561-2571,(2012).","journal-title":"Neurobiol Aging"},{"key":"ref=37","first-page":"45","volume":"10","author":"Overhoff F.","year":"","unstructured":"Overhoff F, Brendel M, Jaworska A, Korzhova V, Delker A, Probst F. Front Neurosci, Automated spatial brain normalization and hindbrain white matter reference tissue give improved [18F]-Florbetaben PET quantitation in Alzheimer\u2019s model mice.,, , 10,, 45-,(2016).","journal-title":"Front Neurosci"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2174\/1567205013666160620114309","volume":"14","author":"Chiaravalloti A.","year":"","unstructured":"Chiaravalloti A, Danieli R, Lacanfora A, Palumbo B, Caltagirone C, Schillaci O. Curr Alzheimer Res, Usefulness of 18F florbetaben in diagnosis of Alzheimer\u2019s disease and other types of dementia.,, , 14,, 154-160,(2017).","journal-title":"Curr Alzheimer Res"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","volume":"3","author":"Sabri O.","year":"","unstructured":"Sabri O, Seibyl J, Rowe C, Barthel H. Clin Transl Imaging, Beta-amyloid imaging with florbetaben.,, , 3,, 13-26,(2015).","journal-title":"Clin Transl Imaging"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13550-014-0037-3","volume":"4","author":"Snellman A.","year":"","unstructured":"Snellman A, Rokka J, L\u00f3pez-Pic\u00f3n FR, Eskola O, Salmona M, Forloni G. EJNMMI Res, In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer\u2019s disease with a high specific activity PET imaging agent [18F]flutemetamol.,, , 4,, 37-,(2014).","journal-title":"EJNMMI Res"}],"container-title":["Current Alzheimer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/166482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T16:51:57Z","timestamp":1720716717000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/166482\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,31]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12,31]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567205015666181022095904","relation":{},"ISSN":["1567-2050"],"issn-type":[{"value":"1567-2050","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,31]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}